NASDAQ NMS - GLOBAL MARKET · CLYM
-1.93% · -$0.2300 · Vol 1.5M
Market closed · last close 4:00 PM ET · price as of 16:09:10 ET
Climb Bio Inc

Climb Bio Inc

Biotechnology
$11.66
Card
Relationship Map

Follow $CLYM

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $CLYM by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
CLYM
Climb Bio Inc
Fri Sep 25 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

67/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Fri Sep 25 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CLYM moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CLYM catalysts
About Climb Bio Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
29
Country
US

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$11.89
Day high
$11.92
Day low
$11.53
Previous close
$11.89
52W high
$17.84
-34.64% from high
52W low
$1.64
62% of range
Market cap
$669.7M
EPS
$-0.7000
Beta
0.84
Shares out
57.4M
Volume
1.5M
0.90× rel vol
Avg volume
1.7M
VWAP
$11.69
Price history computed in-house
1W
-17.01%
1M
-19.97%
3M
-12.72%
1Y
+447.42%
YTD
+191.50%
SMA 50 $14.20 · below
SMA 200 $9.56 · above
52W position 62%

CLYM overview

Veridion Score
67
Registered · 2026-09-25
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CLYM.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CLYM Form 4 filings
Public disclosures

Congress activity in CLYM

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CLYM in the cached public ledger.

Federal contracts

CLYM contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CLYM in this window.
Lobbying spend

CLYM lobbying filings, year to date.

Registered lobbying filings matched to Climb Bio Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CLYM in this window.
Loading news for CLYM
Analyst ratings
Sovereign unlock shows live analyst consensus for CLYM.
Options
Sovereign unlock shows live options positioning for CLYM.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.